1. Home
  2. CRBP vs ARAI Comparison

CRBP vs ARAI Comparison

Compare CRBP & ARAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$7.86

Market Cap

170.3M

Sector

Health Care

ML Signal

HOLD

ARAI

Arrive AI Inc.

N/A

Current Price

$2.66

Market Cap

143.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
ARAI
Founded
2009
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Diversified Commercial Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
170.3M
143.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CRBP
ARAI
Price
$7.86
$2.66
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$50.29
$12.00
AVG Volume (30 Days)
492.2K
116.8K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$98,175.00
Revenue This Year
N/A
N/A
Revenue Next Year
$100.00
$900.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.64
$2.52
52 Week High
$20.56
$40.00

Technical Indicators

Market Signals
Indicator
CRBP
ARAI
Relative Strength Index (RSI) 28.92 N/A
Support Level $7.97 N/A
Resistance Level $8.54 N/A
Average True Range (ATR) 0.47 0.00
MACD 0.04 0.00
Stochastic Oscillator 5.21 0.00

Price Performance

Historical Comparison
CRBP
ARAI

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About ARAI Arrive AI Inc.

Arrive AI Inc is a technology company. Its patented Autonomous Last Mile (ALM) platform enables secure, efficient delivery to and from a smart, AI-powered mailbox-whether by drone, ground robot, or human courier. The platform provides real-time tracking, smart logistics alerts, and advanced chain-of-custody controls to support shippers, delivery services, and autonomous networks. By combining artificial intelligence with autonomous technology, Arrive AI makes the exchange of goods between people, robots, and drones frictionless and convenient. Its system integrates with smart home devices such as doorbells, lighting, and security systems to streamline the entire last-mile delivery experience.

Share on Social Networks: